CD30-Positive Cutaneous T-Cell Lymphoma and Response to Brentuximab Vedotin: 2 Illustrative Cases

被引：11

作者：

Mody, Kabir ^{[1
]}

Wallace, Jill S. ^{[1
]}

Stearns, Diane M. ^{[1
]}

Bowers, George ^{[2
]}

Lacy, Shannon R. ^{[1
]}

Levy, Norman B. ^{[1
]}

Zug, Kathryn A. ^{[1
]}

Lansigan, Frederick ^{[1
]}

机构：

[1] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA

[2] Hampshire Hematol & Oncol, Hematol & Oncol, Northampton, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2013年 / 13卷 / 03期

关键词：

Cutaneous anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Mycosis fungoides; NON-HODGKINS-LYMPHOMA; PHASE-II; IDEC-Y2B8; RADIOIMMUNOTHERAPY; DENILEUKIN DIFTITOX; I-131; TOSITUMOMAB; TRIAL; ALEMTUZUMAB; EXPERIENCE;

D O I：

10.1016/j.clml.2012.12.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：319 / 323

页数：5

共 21 条

[1] Antibody-drug conjugates: targeted drug delivery for cancer [J].

Alley, Stephen C. ;

Okeley, Nicole M. ;

Senter, Peter D. .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) :529-537

[2]

BATES S, 2008, ASH ANN M, V112, P1568

[3] CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival [J].

Duckett, CS ;

Thompson, CB .

GENES & DEVELOPMENT, 1997, 11 (21) :2810-2821

[4] Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results [J].

Duvic, M ;

Hymes, K ;

Heald, P ;

Breneman, D ;

Martin, AG ;

Myskowski, P ;

Crowley, C ;

Yocum, RC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2456-2471

[5]

Duvic M, ASH ANN M, V120

[6] A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma [J].

Forero-Torres, Andres ;

Leonard, John P. ;

Younes, Anas ;

Rosenblatt, Joseph D. ;

Brice, Pauline ;

Bartlett, Nancy L. ;

Bosly, Andre ;

Pinter-Brown, Lauren ;

Kennedy, Dana ;

Sievers, Eric L. ;

Gopal, Ajay K. .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (02) :171-179

[7]

Horwitz SM, 2008, ASH ANN M ABSTR, V112, P1569

[8] Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma:: updated results and long-term follow-up of the University of Michigan experience [J].

Kaminski, MS ;

Estes, J ;

Zasadny, KR ;

Francis, IR ;

Ross, CW ;

Tuck, M ;

Regan, D ;

Fisher, S ;

Gutierrez, J ;

Kroll, S ;

Stagg, R ;

Tidmarsh, G ;

Wahl, RL .

BLOOD, 2000, 96 (04) :1259-1266

[9] Brentuximab Vedotin (SGN-35) [J].

Katz, Jessica ;

Janik, John E. ;

Younes, Anas .

CLINICAL CANCER RESEARCH, 2011, 17 (20) :6428-6436

[10] Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab [J].

Kennedy, GA ;

Seymour, JF ;

Wolf, M ;

Januszewicz, H ;

Davison, J ;

McCormack, C ;

Ryan, G ;

Prince, HM .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) :250-256

← 1 2 3 →